Benitec Biopharma Inc./$BNTC
Benitec Biopharma shares fall after FY26 results showed a wider net loss and higher operating expenses, highlighting continued cash burn despite progress in its BB-301 programme.
4 hours agoLightyear AI
1D1W1MYTD1Y5YMAX
Capital at risk
About Benitec Biopharma Inc.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.
- Ticker
- $BNTC
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 19
- Headquarters
- Hayward, United States
- Website
- benitec.com
BNTC Metrics
BasicAdvanced
$415M
-
-$0.93
0.28
-
Price and volume
Market cap
$415M
Beta
0.28
52-week high
$16.76
52-week low
$9.85
Average daily volume
157K
Financial strength
Current ratio
56.816
Quick ratio
56.434
Long term debt to equity
0.002
Total debt to equity
0.005
Profitability
EBITDA (TTM)
-46.541
Management effectiveness
Return on assets (TTM)
-19.93%
Return on equity (TTM)
-29.58%
Valuation
Price to book
2.26
Price to tangible book (TTM)
2.26
Price to free cash flow (TTM)
-27.118
Free cash flow yield (TTM)
-3.69%
Free cash flow per share (TTM)
-0.445
Growth
Earnings per share change (TTM)
-10.64%
3-year earnings per share growth (CAGR)
-62.87%
10-year earnings per share growth (CAGR)
-47.81%
Bulls say / Bears say
Interim BB-301 data show a potentially meaningful and durable treatment effect: all four assessed low-dose patients improved, with one followed for two years, while early high-dose results also showed deeper responses. This supports the possibility of a one-off, disease-modifying treatment for OPMD-related swallowing problems. (Muscular Dystrophy News, Benitec Biopharma)
Benitec has moved towards a pivotal study, holding an FDA Type C meeting on its design in the third quarter and targeting trial initiation in mid-2027. The planned October presentation of updated Cohort 1 and Cohort 2 data provides a near-term clinical catalyst. (RTT News)
The company ended June 2026 with $180 million in cash and cash equivalents. That balance is intended to fund operations for at least the next twelve months, reducing the immediate risk of a financing interruption while BB-301 advances. (Stock Titan, RTT News)
BB-301 remains an early, open-label Phase 1b/2a programme with only six low-dose and three high-dose patients treated. The encouraging results still need confirmation in a larger, controlled pivotal study before they can support approval. (RTT News, Stock Titan)
Benitec had no product revenue in fiscal 2026 and its net loss widened to $45.5 million from $37.9 million. That leaves the company dependent on external funding while BB-301 remains uncommercialised. (TradingView, RTT News)
Benitec has registered up to $200 million of additional securities and says it will need more financing to reach future development milestones. Any future share issuance could dilute existing investors, particularly if clinical progress takes longer than planned. (Stock Titan)
Data summarised monthly by Lightyear AI. Last updated on 15 Sept 2026.
Upcoming events
No upcoming events
Funds containing BNTC
Fund name | Fund size | $BNTC weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.00% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.